Prospective Trial of Minimal Residual Disease Assessment by Multiparametric Flow Cytometry for Multiple Myeloma in the Era of Bortezomib-Based Chemotherapy
2018 ◽
Vol 24
(3)
◽
pp. S139-S140
2018 ◽
Vol 53
(12)
◽
pp. 1589-1592
◽
Keyword(s):
2019 ◽
Vol 94
(5)
◽
pp. 512-521
◽
2015 ◽
Vol 15
◽
pp. e185
◽
2012 ◽
Vol 89
(4)
◽
pp. 328-335
◽